Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche has expanded its collaboration with biotherapeutics company Xencor to create monoclonal antibodies with differentiated pharmacological profiles for the treatment of cancer.
Subscribe to our email newsletter
Roche and Xencor entered into the initial collaboration in January 2005, in which Roche applies Xencor’s XmAb Fc domains with the aim of enhancing the therapeutic efficacy of an antibody against a cancer target. This extension allows Roche to further its research efforts against the target.
“We are very pleased to continue working with Roche to apply our XmAb proprietary engineered Fc domains to enhance the efficacy of Roche’s proprietary antibodies,” said Dr Bassil Dahiyat, president and CEO of Xencor.
Under the original collaboration, Xencor received technology access and license fees, and is eligible to receive additional license fees, milestones and royalties in the event that Roche advances candidates into development.
Xencor will receive additional fees for the extension. Specific financial terms were not disclosed.